A hepatitis C cure that cost $84,000 in one country and $240 in another

The patient was diagnosed incidentally when routine blood tests showed raised liver enzymes. Confirmatory HCV RNA testing established chronic infection with genotype 1, and fibrosis assessment showed no cirrhosis.

The clinical news was good: modern direct-acting antivirals cure more than 95% of people with a finite 8 to 12 week oral course, and WHO documents these cure rates. There is no lifelong therapy involved. It is a defined course with a defined endpoint.

The financial news was not. The list price quoted for the recommended regimen was approximately $84,000 for 12 weeks — a figure that became a global reference point in the medicine pricing debate.

The active ingredients in these regimens are not expensive to manufacture at scale. The price difference is a function of patent status and licensing territory, not production cost.

The originator granted voluntary licences allowing named generic manufacturers — several based in India — to produce and supply the molecule across a defined list of countries. The Medicines Patent Pool documents this licensing model and its measured public-health impact.

This is authorised parallel supply, not a grey market. The same molecule, produced under licence, legitimately sells for a few hundred dollars per course in those territories.

He did not import anything. His hepatologist referred him to a state hepatitis C elimination programme, which had negotiated bulk pricing and covered treatment for eligible residents.

This matters, because the instinctive reaction to a price gap is to look abroad. In this case the domestic public programme was faster, fully supervised, and cost him nothing.

1. 1Hepatologist confirmed genotype and fibrosis stage.
2. 2Hepatitis B screening completed, since reactivation is a recognised risk during therapy.
3. 3Full drug-interaction review against his other medicines.
4. 4Referral to the state elimination programme and eligibility assessment.
5. 5Twelve-week course completed with adherence support.
6. 6Sustained virological response confirmed by testing 12 weeks after completion.

The post-treatment test confirmed sustained virological response — cure. He requires ongoing liver health monitoring, but the chronic infection is gone and the risk trajectory toward cirrhosis and liver cancer is fundamentally altered.

The lesson generalises beyond hepatitis C. When a medicine looks unaffordable, the correct first question is not 'where can I buy this cheaper' but 'what public programme, assistance scheme or licensed pathway already exists for this exact condition'.

This is a composite case study. It illustrates a real, documented price pattern using a representative patient profile rather than a specific identifiable individual. Figures are reference ranges, not quotations, and outcomes vary by person, dose and market.

Statistics alone cannot carry the weight of a decision about medicine. A line like 'the same course is 340 times cheaper' means nothing until you can see what it did to one household's bills, monitoring schedule and peace of mind.

The only reason we show any switch is to illustrate a pattern. Your own move must be planned with your prescriber.

Jivan publishes pricing and educational information only. Do not start, stop, substitute or re-dose any medicine without a licensed physician's approval.